GoodRx Holdings, Inc.

GoodRx Holdings, Inc.

GDRX
GoodRx Holdings, Inc.US flagNASDAQ Global Select
2.95
USD
-0.13
- -
1.02BMarket Cap
GoodRx Holdings, Inc.
GDRX
(NASDAQ Global Select)

Recent

price

2.95

P/E

ratio

- -

div

yld

- -

ROIC.AI

2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
0.7
1.09
2
1.82
1.86
1.83
2.05
2.24
2.28
Revenue per Share
0.12
0.19
-1.07
-0.06
-0.08
-0.02
0.04
0.09
0.06
Basic EPS, GAAP
0.12
0.22
0.4
0.42
0.35
0.33
0.47
0.46
0.48
Free Cash Flow per Basic Share
3.78
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-3.26
-3.08
-5.06
-3.45
-3.51
-3.55
-3.74
-3.96
-4.07
Book Value per Share
-3.93
-3.79
1.43
0.9
0.52
0.47
0.36
-0.05
-0.03
Tangible Book Value per Share
356
356
275
410
413
410
386
356
346
Basic Weighted Avg Shares
250
388
551
745
767
750
792
797
788
Sales/Revenue/Turnover
30.96
35.98
-50.07
1.8
0.23
-3.6
8.31
10.98
9.92
Operating Margin (%)
10
14
18
35
54
108
70
85
86
Depreciation Expense
44
66
-294
-25
-33
-9
16
30
21
Net Income, GAAP
16.34
20.4
- -
- -
- -
- -
47.9
46.16
54.83
Effective Tax Rate (%)
17.55
17.01
-53.32
-3.39
-4.28
-1.18
2.07
3.82
2.61
Profit Margin (%)
56
53
1,027
1,008
843
750
535
397
407
Working Capital
717
701
693
689
706
696
533
533
531
LT Debt
-1,162
-1,088
711
832
815
762
725
616
622
Total Equity
- -
- -
- -
- -
- -
- -
2.5
3.88
2.98
Return on Invested Capital (%)
- -
-25.56
- -
- -
- -
- -
-5.35
-6.05
-4.49
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
10
10
10
LT Borrowings
484
483
482
LT Finance Leases
51
50
49
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
341
341
338
Market Capitalization
1,548
964
678

Working Capital

FRC

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
566
643
1,266
Cash, Cash Equivalents & STI
274
262
236
Accounts Receivable, Net
204
236
233
Inventories
- -
- -
- -
Total Current Liabilities
182
246
859
Payables & Accruals
124
99
90
ST Debt
10
10
10
Deferred Revenue
6
7
9

Growth Rates

FRC

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
-2.29%
-14.96%
Free Cash Flow
- -
11.68%
-10%
Net Income, GAAP
- -
-66.7%
85.72%
Sales/Revenue/Turnover
- -
8.45%
0.57%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
198
201
195
199
792
2025
203
203
196
195
797
2026
194
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
0.02
0.01
0.02
0.04
2025
0.03
0.04
- -
0.02
0.09
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Business
GoodRx Holdings, Inc. (GDRX) operates a leading digital healthcare platform in the United States that provides prescription price comparison, discount coupons, and access to negotiated pricing across more than 75,000 pharmacies; its core offerings include the prescription marketplace with transaction services from pharmacy benefit managers (PBMs), supplemental subscriptions like GoodRx Gold, telehealth consultations via GoodRx Care at a flat fee regardless of insurance, medical testing services, and pharma manufacturer solutions such as co-pay cards, patient assistance programs, and care portals. The Santa Monica, California-based company, founded in 2011, generates revenue primarily from PBM partnerships managing formularies and pricing, pharma manufacturer advertising integrated into its platform, subscription fees, and telehealth visits on a cash-pay basis; it serves consumers, healthcare professionals, payers, PBMs, manufacturers, and retail pharmacies nationwide, with deep relationships including Walgreens, Walmart, CVS Caremark, Publix, Express Scripts, MedImpact, Affirm, and DoorDash for enhanced savings and flexibility. Recent developments include a 2025 collaboration with Novo Nordisk to offer Ozempic and Wegovy at $499 per month for self-paying patients across over 70,000 pharmacies, an expanded partnership with Kroger to deploy the RxSmartSaver program for discounted branded drugs including GLP-1 weight loss medications at 2,200 pharmacies in 35 states, a new partnership with Amgen for Repatha at nearly 60% off list price, potential alignment with TrumpRx initiatives for direct-to-consumer drug discounts, the appointment of Laura Jensen as Chief Commercial Officer and President of Pharma Solutions from Amazon Pharmacy in July 2025 to bolster manufacturer partnerships, and projected 35% growth in manufacturer solutions for 2025 amid Q3 2025 revenue beats driven by this segment.

Company News

APIChat
  • GoodRx Launches GoodRx Companion, a New Subscription Designed to Lower Everyday Healthcare Costs

  • GoodRx Launches GoodRx Companion, a New Subscription Designed to Lower Everyday Healthcare Costs

  • 3 Reasons Retirees Should Reconsider Enrolling in a Standalone Medicare Drug Plan in 2026

  • GoodRx: TrumpRx Exposes Legacy Moat Breach And Zero-Sum Strategy (Downgrade)

  • GoodRx Holdings, Inc. (GDRX) Q1 2026 Earnings Call Transcript

  • Big Pharma Runs Its Checkout Counter Through GoodRx

  • Should You Add OPRX Stock to Your Portfolio Pre-Q1 Earnings?

  • GoodRx (GDRX) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

  • GoodRx Holdings, Inc. (GDRX) Q1 Earnings Match Estimates

  • GoodRx Reports First Quarter 2026 Results

  • GoodRx Expands Offerings to Now Include Ozempic® Pill for Type 2 Diabetes Patients

  • Hims & Hers Expands Digital-First Access to Personalized Healthcare

  • OptimizeRx vs. GoodRx: Which Digital Health Stock is the Better Buy?

  • GoodRx Announces Date for First Quarter 2026 Earnings Release and Conference Call

  • GoodRx Rallies As Wegovy HD Rollout Targets Self-Pay Market

  • GoodRx Now Offers Access to Wegovy® HD at $399 Per Month Self-Pay Price

  • GoodRx Expands Access to Eli Lilly and Company's New Oral GLP-1, Foundayo™, and Zepbound® KwikPen® with Self-Pay Pricing at More Than 70,000 Pharmacies Nationwide

  • Reviewing GoodRx (NASDAQ:GDRX) & Nutex Health (NASDAQ:NUTX)

  • GoodRx (NASDAQ:GDRX) versus Biocorrx (OTCMKTS:BICX) Critical Comparison

  • GoodRx Partners with Viatris to Offer Up to 85% Savings on Established Brand Medications